Delivering fully validated biosimilar assets with supporting
data to jump start your development efforts.
Our differentiated approach enables rapid biosimilar target selection, accelerates Chemistry, Manufacturing, and Controls development timelines, and reduces preclinical cost and risk. Learn more about our programs by exploring our pipelines.
Reduce risk during early biosimilar development, cut costs for analytical activities, and accelerate early programs.
Are you looking for a program beyond our current pipeline but you are concerned with risks from program cancellation and market timelines? Discuss a co-development agreement with Similis to initiate the development of multiple biosimilar programs in parallel with an exclusive right to every program.